Cetirizine (Systemic) - Drug Information - UpToDate

13/10/22, 18:18 Cetirizine (systemic): Drug information - UpToDate
Reimpresión oficial de UpToDate ®

www.uptodate.com © 2022 UpToDate, Inc. y/o sus afiliados. Reservados todos los derechos.
Cetirizina (sistémica): información sobre medicamentos
Copyright 1978-2022 Lexicomp, Inc. Todos los derechos reservados.
Divulgaciones de contribuyentes
(Para obtener información adicional, consulte "Cetirizina (sistémica): Información sobre el medicamento para el paciente" y consulte "Cetirizina (sistémica):
Información sobre el medicamento pediátrico" )
Para consultar las definiciones de abreviaturas, símbolos y grupos de edad utilizados en Lexicomp ( ver tabla )
Nombres de marca: EE. UU.

All Day Allergy Childrens [OTC] [DSC];
Alergia todo el día [OTC] [DSC];
Alergia (Cetirizina) [OTC];
alivio de alergias (cetirizina) [de venta
libre];
Cetirizina para el alivio de alergias [OTC];
Alivio de alergias para niños [OTC];
alivio de alergias [OTC];
alivio de
alergias/interiores/exteriores [de venta libre];
Cetirizina HCl Alergia Niño [OTC];
Cetirizina HCl Childrens Alrgy [OTC];
Cetirizina HCl
Childrens [OTC] [DSC];
Alivio de la urticaria con clorhidrato de cetirizina [OTC];
GoodSense All Day Allergy [de venta libre];
Quzyttir;
ZyrTEC Allergy Childrens [de venta libre];
alergia ZyrTEC [de venta libre];
Alergia infantil ZyrTEC [OTC];
ZyrTEC [de venta libre]
Marcas comerciales: Canadá

AG-cetirizina;
APO-Cetirizina;
JAMP-Cetirizina;
M-cetirizina;
Mar-Cetirizina;
MENTA-Cetirizina;
NRA-Cetirizina;
PMS-Cetirizina;
Priva-
Cetirizina [DSC];
reactina
Categoría farmacológica
antagonista de histamina H1 ;
antagonista de histamina H1 , segunda generación;
Derivado de piperazina
https://www.uptodate.com/contents/cetirizine-systemic-drug-information/print?search=cetirizina&source=panel_search_result&selectedTitle=1~97&usage_type=panel&showDrugLabel=true&display_rank=1 1/33
Posología: Adulto
Collapse All
Rinitis alérgica o conjuntivitis 
Rinitis alérgica o conjuntivitis: Oral: 10 mg una vez al día; alternativamente, se puede administrar según sea necesario de 2 a 5
horas antes de la exposición al alérgeno, aunque esto puede ser menos efectivo que la administración diaria ( Ref ).
Etiquetado OTC (terapia guiada por el paciente para los síntomas de la fiebre del heno u otras alergias de las vías respiratorias
superiores): 5 a 10 mg una vez al día (máximo: 10 mg/día).
Anafilaxia 
Anafilaxia (complemento de la epinefrina para el alivio de los síntomas cutáneos) (uso no indicado en la etiqueta): Nota:
No se use como tratamiento inicial o único de la anafilaxia porque los antihistamínicos H 1 no alivian la obstrucción de las vías
respiratorias superiores o inferiores ni el shock ( Ref .).
IV, Oral: 10 mg en dosis única ( Ref ).
Angioedema, alérgico agudo o idiopático recurrente 
Angioedema, alérgico agudo o idiopático recurrente (uso fuera de etiqueta): Nota: No está indicado para angioedema con
anafilaxia; use epinefrina si hay síntomas de anafilaxia (es decir, hay riesgo de compromiso cardiovascular o de las vías
respiratorias) ( Ref ).
Oral: 10 mg una o dos veces al día; puede aumentar hasta 20 mg dos veces al día ( Ref ).
Infusion reaction, premedication 

Infusion reaction, premedication (adjunct) (alternative agent) (off-label use): Note: Used in some protocols as an alternative
to a sedating antihistamine (eg, diphenhydramine). An optimal premedication regimen has not been identified; refer to
institutional protocols as variations exist (Ref).
Oral: 10 mg typically administered 30 to 60 minutes prior to infusion of certain chemotherapy agents or biologics; may be
given with an H2 antihistamine (eg, ranitidine) and/or a glucocorticoid (Ref).
Urticaria, new onset and chronic spontaneous 
Urticaria, new onset and chronic spontaneous:
New onset:
Oral (off-label use): Initial: 10 mg once daily. If symptom control is inadequate, may immediately increase to 10 mg twice
daily (Ref).
IV: 10 mg once daily as needed.
Chronic spontaneous:
Oral: Initial: 10 mg once daily. If symptom control is inadequate, may increase in increments of 10 mg/day every 1 to 4
weeks up to 20 mg twice daily. Periodically reevaluate necessity for continued treatment (Ref).
Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or
avoidance. Consult drug interactions database for more information.
Dosing: Kidney Impairment: Adult
The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce
Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
IV: No dosage adjustment necessary (formulation only intended for short-term use).
Oral: Note: Renally adjusted dose recommendations are based on usual doses of 5 to 10 mg once daily.
Altered kidney function:
CrCl >31 mL/minute: No dosage adjustment necessary.
CrCl 11 to ≤31 mL/minute: 5 mg once daily.
CrCl ≤10 mL/minute: 5 mg once every 48 hours; may increase to 5 mg once daily based on tolerability and response for
short-term use only (drug may accumulate with prolonged use at this dose (Ref)).
Hemodialysis, intermittent (thrice weekly): <10% dialyzable; 5 mg 3 times per week (Ref); may increase to 5 mg once daily
based on tolerability and response for short-term use only (drug may accumulate with prolonged use at this dose (Ref)).
Peritoneal dialysis: Unlikely to be significantly dialyzed (Ref): 5 mg once every 48 hours; may increase to 5 mg once daily based
on tolerability and response for short-term use only (drug may accumulate with prolonged use at this dose (Ref).
Dosing: Hepatic Impairment: Adult

Mild to severe impairment: 5 mg once daily.
Dosing: Pediatric
(For additional information see "Cetirizine (systemic): Pediatric drug information")

Collapse All
Allergic symptoms, hay fever 
Allergic symptoms, hay fever:
Children 2 to 5 years: Oral: Initial: 2.5 mg once daily; dosage may be increased to 2.5 mg twice daily or 5 mg once daily;
maximum daily dose: 5 mg/day.
Children ≥6 years and Adolescents: Oral: 5 to 10 mg once daily.
Anaphylaxis; adjunctive for cutaneous symptoms 
Anaphylaxis; adjunctive for cutaneous symptoms: Limited data available (Ref): Note: Do not use for initial or sole treatment of
anaphylaxis; H1 antihistamines are not effective for upper or lower airway obstruction or shock (Ref). If cutaneous symptoms
persist, dose may be repeated in 24 hours (see Urticaria, acute dosing).
Infants ≥6 months and Children <2 years: Oral: 2.5 mg once.
Children 2 to 5 years: Oral 2.5 to 5 mg once.
Children >5 years and Adolescents: Oral: 5 to 10 mg once.
Rhinitis, allergic 
Rhinitis, allergic (perennial):
Infants 6 to <12 months: Oral: 2.5 mg once daily.
Children 12 to 23 months: Oral: Initial: 2.5 mg once daily; dosage may be increased to 2.5 mg twice daily.
Urticaria, acute 
Urticaria, acute:
IV:
Infants ≥6 months to Children ≤5 years: 2.5 mg every 24 hours.
Children 6 to 11 years: 5 mg or 10 mg every 24 hours; reserve higher dose for more severe symptoms.
Children ≥12 years and Adolescents: 10 mg every 24 hours.
Oral: Limited data available (Ref):
Infants ≥6 months and Children <2 years: Oral: 2.5 mg once daily.
Children 2 to 5 years: Oral: 2.5 to 5 mg once daily.
Children >5 years and Adolescents: Oral: 5 to 10 mg once daily.
Urticaria, chronic spontaneous 
Urticaria, chronic spontaneous: Limited data available in Children >5 years and Adolescents. Note: Considered first-line therapy
for management of chronic urticaria; if response inadequate after 2 to 4 weeks of therapy or symptoms intolerable, consider
increasing the dose of cetirizine (as age and weight permits) as second-line treatment rather than changing therapy (Ref).
Infants 6 to <12 months: Oral: 2.5 mg once daily.
Infants ≥12 months and Children <2 years: Oral: Initial: 2.5 mg once daily; dosage may be increased to 2.5 mg twice daily.
Children 2 to 5 years: Oral: Initial: 2.5 mg once daily; dosage may be increased to 2.5 mg twice daily or 5 mg once daily;
maximum daily dose: 5 mg/day.
Children 6 to 11 years: Oral: 5 mg once daily or twice daily (Ref).
Children ≥12 years and Adolescents: Oral: 10 mg once daily (Ref).
Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or
avoidance. Consult drug interactions database for more information.
Dosing: Kidney Impairment: Pediatric
IV: Note: Has only been evaluated for acute indications (short-term therapy).
Infants ≥6 months and Children <6 years: Avoid use in patients with any degree of renal impairment; has not been studied.
Children ≥6 years and Adolescents: Moderate to severe impairment; end-stage renal disease on dialysis: No adjustment
necessary; monitor for antihistamine side effects and adjust therapy if needed.
Oral: There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been
recommended (Ref):
Infants, Children, and Adolescents:
GFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.
GFR 10 to 29 mL/minute/1.73 m2: Decrease dose by 50%.
GFR <10 mL/minute/1.73 m2: Not recommended.
Intermittent hemodialysis or peritoneal dialysis: Decrease dose by 50%.
Dosing: Hepatic Impairment: Pediatric
IV: Note: Has only been evaluated for acute indications (short-term therapy).
Infants ≥6 months to Children <6 years: Avoid use with hepatic impairment; has not been studied.
Children ≥6 years and Adolescents: No dosage adjustment required; monitor for antihistamine side effects and adjust therapy if
needed.
Oral: Infants ≥6 months, Children, and Adolescents: There are no dosage adjustments provided in manufacturer's labeling.
Dosing: Older Adult

Upper respiratory allergies, urticaria: Oral: 5 mg once daily (maximum dose: 5 mg daily). The previously available prescription product
recommended a maximum dose of 10 mg once daily in patients <77 years of age or 5 mg once daily in patients ≥77 years of age (Ref).
Dosage Forms: US
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] =
Discontinued product
Capsule, Oral, as hydrochloride:
Allergy Relief: 10 mg
ZyrTEC Allergy: 10 mg
Solution, Intravenous, as hydrochloride [preservative free]:
Quzyttir: 10 mg/mL (1 mL)
Solution, Oral, as hydrochloride:
All Day Allergy Childrens: 5 mg/5 mL (118 mL [DSC]) [dye free, gluten free; contains methylparaben, propylene glycol,
propylparaben]
Allergy Relief Childrens: 5 mg/5 mL (118 mL) [dye free, sugar free; contains propylene glycol, sodium benzoate; grape flavor]
Cetirizine HCl Allergy Child: 5 mg/5 mL (120 mL) [alcohol free, dye free, gluten free, sugar free; contains methylparaben,
propylene glycol, propylparaben; grape flavor]
Cetirizine HCl Allergy Child: 5 mg/5 mL (120 mL) [alcohol free, sugar free; contains methylparaben, propylene glycol,
propylparaben; grape flavor]
Cetirizine HCl Allergy Child: 5 mg/5 mL (118 mL) [dye free, gluten free, sugar free; contains propylene glycol, sodium benzoate;
grape flavor]
Cetirizine HCl Childrens: 5 mg/5 mL (118 mL [DSC]) [contains methylparaben, propylene glycol, propylparaben]
Cetirizine HCl Childrens Alrgy: 5 mg/5 mL (118 mL, 120 mL [DSC]) [contains methylparaben, propylene glycol, propylparaben;
grape flavor]
Cetirizine HCl Hives Relief: 5 mg/5 mL (120 mL) [alcohol free, sugar free; contains methylparaben, propylene glycol,
propylparaben; grape flavor]
GoodSense All Day Allergy: 5 mg/5 mL (118 mL) [dye free, gluten free, sugar free; contains propylene glycol, sodium benzoate;
grape flavor]
GoodSense All Day Allergy: 5 mg/5 mL (118 mL) [dye free, gluten free, sugar free; contains propylene glycol, sodium benzoate,
sorbitol]
ZyrTEC Childrens Allergy: 5 mg/5 mL (118 mL) [dye free, sugar free; contains propylene glycol, sodium benzoate]
ZyrTEC Childrens Allergy: 5 mg/5 mL (30 mL, 118 mL, 236 mL) [dye free, sugar free; contains propylene glycol, sodium benzoate;
grape flavor]
Generic: 5 mg/5 mL (120 mL, 473 mL, 480 mL)
Tablet, Oral, as hydrochloride:
All Day Allergy: 10 mg [DSC] [contains corn starch]
Allergy (Cetirizine): 10 mg [scored]
Allergy Relief (Cetirizine): 10 mg
Allergy Relief Cetirizine: 5 mg [contains corn starch]
Allergy Relief Cetirizine: 10 mg
Allergy Relief Cetirizine: 10 mg [contains corn starch]
Allergy Relief/Indoor/Outdoor: 10 mg [scored]
GoodSense All Day Allergy: 10 mg [gluten free; contains corn starch, fd&c blue #1 aluminum lake]
ZyrTEC Allergy: 10 mg
Generic: 5 mg, 10 mg
Tablet Chewable, Oral:
ZyrTEC Childrens Allergy: 2.5 mg [dye free; contains corn starch; grape flavor]
Tablet Chewable, Oral, as hydrochloride:
Cetirizine HCl Childrens: 5 mg [DSC], 10 mg [DSC] [contains aspartame, fd&c yellow #6 aluminum lake]
ZyrTEC: 10 mg [dye free; contains corn starch]
ZyrTEC Childrens Allergy: 10 mg [dye free; contains corn starch]
Generic: 5 mg, 10 mg
Tablet Disintegrating, Oral, as hydrochloride:
ZyrTEC Allergy: 10 mg [DSC]
ZyrTEC Allergy Childrens: 10 mg

ZyrTEC Allergy Childrens: 10 mg [citrus flavor]
Generic Equivalent Available: US

May be product dependent
Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Tablet, Oral, as hydrochloride:
Reactine: 20 mg
Generic: 20 mg
Administration: Adult
Oral: May be administered with or without food.
Chewable tablet: Chew tablet before swallowing; may be taken with or without water.
IV: Injection: For IV use only; do not administer IM or SUBQ; administer as an IV push over 1 to 2 minutes.
Administration: Pediatric
Oral: Administer without regard to food.
Chewable tablet: Chew tablet before swallowing; may be taken with or without water.
Dissolving tablet: Allow tablet to melt in mouth; may be taken with or without water.
Liquid: Administer with an accurate measuring device; do not use a household teaspoon (overdosage may occur).
Parenteral: IV: Administer IV undiluted over 1 to 2 minutes; do not administer IM or SubQ.
Use: Labeled Indications
Oral:
Allergic rhinitis: Relief of symptoms associated with allergic rhinitis.
Urticaria, chronic spontaneous: Treatment of uncomplicated skin manifestations of chronic spontaneous urticaria.
Injection:
Urticaria, new onset: Treatment of new-onset (acute) urticaria.
Use: Off-Label: Adult
Anaphylaxis (adjunct to epinephrine for relief of cutaneous symptoms); Angioedema, acute allergic or recurrent idiopathic; Infusion
reaction, premedication
Medication Safety Issues

Sound-alike/look-alike issues:
Cetirizine may be confused with sertraline, stavudine
Quzyttir may be confused with Qsymia
ZyrTEC may be confused with Lipitor, Serax, Xanax, Zantac, Zerit, Zocor, ZyPREXA, ZyrTEC-D
International issues:
Benadryl international brand name for cetirizine [Great Britain, Philippines], but also the brand name for acrivastine and
pseudoephedrine [Great Britain] and several products containing diphenhydramine [US, Canada]
Adverse Reactions (Significant): Considerations

CNS effects
Cetirizine may cause CNS depression, including sedated state, drowsiness, and fatigue (Ref). There are rare reports of psychosis
and delusion (Ref). In overdose in children, sedation is more likely to occur than with other second-generation antihistamines (Ref).
Mechanism: Dose-related; low brain uptake, binding to ~30% of H1 cerebral receptors (Ref).
Onset: May occur after 1 or 2 doses (Ref). Onset of psychosis has occurred 2 to 7 days after initiation of cetirizine (Ref).
Risk factors:
• Concurrent alcohol use (Ref)
• Older patients (Ref)
• More sedating than other second-generation antihistamines, including loratadine and fexofenadine, but less sedating
than first-generation antihistamines such as diphenhydramine (Ref)
Adverse Reactions
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
>10%: Nervous system: Drowsiness (adolescents and adults: 11% to 14%; children: 2% to 4%) ( table 1), headache (children: 14%;
adults: <1%)
1% to 10%:
Cardiovascular: Cardiac failure (<2%), chest pain (<2%), edema (<2%), facial edema (<2%), flushing (<2%), hypertension (<2%),
lower extremity edema (<2%), palpitations (<2%), peripheral edema (<2%), syncope (<2%), tachycardia (<2%)
Dermatologic: Acne vulgaris (<2%), alopecia (<2%), bullous rash (<2%), cutaneous nodule (<2%), dermatitis (<2%), diaphoresis
(<2%), eczema (<2%), erythematous rash (<2%), furunculosis (<2%), hyperkeratosis (<2%), hypertrichosis (<2%), maculopapular
rash (<2%), pallor (<2%), pruritus (<2%), seborrhea (<2%), skin photosensitivity (<2%), skin rash (<2%), urticaria (<2%), xeroderma
(<2%)
Endocrine & metabolic: Decreased libido (<2%), dehydration (<2%), diabetes mellitus (<2%), heavy menstrual bleeding (<2%), hot
flash (<2%), increased thirst (<2%), intermenstrual bleeding (<2%), weight gain (<2%)
Gastrointestinal: Abdominal pain (children: 4% to 6%), ageusia (<2%), anorexia (<2%), aphthous stomatitis (<2%), constipation
(<2%), dental caries (<2%), diarrhea (children: 2% to 3%), dysgeusia (<2%), dyspepsia (<2%), enlargement of abdomen (<2%),
eructation (<2%), flatulence (<2%), gastritis (<2%), hemorrhoids (<2%), increased appetite (<2%), melena (<2%), nausea (children:
3%), sialorrhea (<2%), stomatitis (<2%), tongue discoloration (<2%), vomiting (children: 2% to 3%), xerostomia (adolescents and
adults: 5%)
Genitourinary: Cystitis (<2%), dysmenorrhea (<2%), dysuria (<2%), hematuria (<2%), leukorrhea (<2%), mastalgia (<2%), urinary
frequency (<2%), urinary incontinence (<2%), urinary retention (<2%), urinary tract infection (<2%), vaginitis (<2%)
Hematologic & oncologic: Hemophthalmos (<2%), lymphadenopathy (<2%), purpuric disease (<2%), rectal hemorrhage (<2%)
Hepatic: Hepatic insufficiency (<2%)
Hypersensitivity: Angioedema (<2%), tongue edema (<2%)
Nervous system: Abnormality in thinking (<2%), agitation (<2%), altered sense of smell (<2%), amnesia (<2%), anxiety (<2%),
ataxia (<2%), confusion (<2%), depersonalization (<2%), depression (<2%), dizziness (adolescents and adults: 2%), emotional
lability (<2%), euphoria (<2%), fatigue (4% to 6%) ( table 2), hyperesthesia (<2%), hypertonia (<2%), hypoesthesia (<2%),
impaired concentration (<2%), insomnia (≤9%), malaise (≤4%), migraine (<2%), myasthenia (<2%), nervousness (<2%), nightmares
(<2%), pain (<2%), paralysis (<2%), paresthesia (<2%), rigors (<2%), sleep disorder (<2%), twitching (<2%), vertigo (<2%), voice
disorder (<2%)
Neuromuscular & skeletal: Arthralgia (<2%), arthritis (<2%), asthenia (<2%), back pain (<2%), hyperkinetic muscle activity (<2%),
lower limb cramp (<2%), myalgia (<2%), myelitis (<2%), osteoarthrosis (<2%), tremor (<2%)
Ophthalmic: Accommodation disturbance (<2%), blepharoptosis (<2%), blindness (<2%), conjunctivitis (<2%), eye pain (<2%),
glaucoma (<2%), periorbital edema (<2%), visual field defect (<2%), xerophthalmia (<2%)
Otic: Deafness (<2%), otalgia (<2%), ototoxicity (<2%), tinnitus (<2%)
Renal: Polyuria (<2%)
Respiratory: Bronchitis (<2%), bronchospasm (children: 3%), dyspnea (<2%), epistaxis (children: 4%), hyperventilation (<2%),
increased bronchial secretions (<2%), nasal polyposis (<2%), pharyngitis (2% to 6%), pneumonia (<2%), respiratory system
disorder (<2%), rhinitis (<2%), sinusitis (<2%), upper respiratory tract infection (<2%)
Miscellaneous: Fever (<2%)
<1%:
Cardiovascular: Presyncope
Dermatologic: Hyperhidrosis
Nervous system: Feeling hot
Frequency not defined:
Hepatic: Increased serum transaminases (transient, reversible)
Nervous system: Irritability
Miscellaneous: Fussiness in an infant or toddler
Postmarketing:
Cardiovascular: Severe hypotension
Gastrointestinal: Cholestasis (Fong 2000)

Hematologic & oncologic: Hemolytic anemia, thrombocytopenia
Hepatic: Hepatitis (Pompili 2004), increased serum bilirubin
Hypersensitivity: Anaphylaxis (Afonso 2009)
Nervous system: Aggressive behavior, delusion (Garden 2013), hallucination, psychosis (Croitoru 2021), sedated state (Corsico
2019), seizure, suicidal ideation, suicidal tendencies
Neuromuscular & skeletal: Orofacial dyskinesia (Romo 2011)
Renal: Glomerulonephritis
Contraindications
Hypersensitivity to cetirizine, hydroxyzine, levocetirizine, or any component of the formulation.
Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to piperazine derivatives; severe renal
impairment (CrCl <10 mL/minute).
Warnings/Precautions
Disease-related concerns:
• Hepatic impairment: Use with caution; consider dosage adjustment.
• Renal impairment: Use with caution; consider dosage adjustment.
Concurrent drug therapy issues:
• Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.
Special populations:
• Older adult: Use with caution in elderly patients; may be more sensitive to adverse effects.
Warnings: Additional Pediatric Considerations

Safety and efficacy for the use of cough and cold products in pediatric patients <4 years of age is limited; the AAP warns against the use
of these products for respiratory illnesses in young children. Serious adverse effects including death have been reported. Many of these
products contain multiple active ingredients, increasing the risk of accidental overdose when used with other products. The FDA does
not recommend OTC uses for these products in pediatric patients <2 years of age and recommends to use with caution in pediatric
patients ≥2 years of age. Health care providers are reminded to ask caregivers about the use of OTC cough and cold products in order to
avoid exposure to multiple medications containing the same ingredient (AAP 2018; CDC 2007; FDA 2017; FDA 2018).
Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg,
>3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal
failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures,
and respiratory depression; use caution (AAP 1997; Shehab 2009).
Metabolism/Transport Effects
Substrate of CYP3A4 (minor), P-glycoprotein/ABCB1 (minor); Note: Assignment of Major/Minor substrate status based on clinically
relevant drug interaction potential
Drug Interactions
(For additional information: Launch drug interactions program)
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4
Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management
recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.
Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish
the therapeutic effect of Acetylcholinesterase Inhibitors. Risk C: Monitor therapy
Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination
Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Risk C: Monitor therapy
Alizapride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents. Risk C: Monitor therapy
Amezinium: Antihistamines may enhance the stimulatory effect of Amezinium. Risk C: Monitor therapy
Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents. Risk C: Monitor therapy
Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination
Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management:
Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects
have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects. Risk D: Consider therapy modification
Betahistine: May diminish the therapeutic effect of Antihistamines. Antihistamines may diminish the therapeutic effect of
Betahistine. Risk C: Monitor therapy
Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Management: Use caution if coadministering
blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not
be coadministered with blonanserin. Risk D: Consider therapy modification
Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents. Risk C: Monitor therapy
Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. Risk C: Monitor therapy
Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Bromopride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Bromperidol: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination
Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses
of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate
buprenorphine at lower doses in patients already receiving CNS depressants. Risk D: Consider therapy modification
Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products.
Risk C: Monitor therapy
Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products.
Risk C: Monitor therapy
Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents. Risk C: Monitor therapy
Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of
excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a
combination must be used. Risk D: Consider therapy modification
Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants. Risk C: Monitor therapy
Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. Risk X: Avoid combination
CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine. Management: Consider alternatives to this
combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider
prophylactic laxative treatment. Risk D: Consider therapy modification
CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants. Risk C: Monitor therapy
Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or
any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant
with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification
DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine. Management: Monitor for
increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of
either agent to avoid excessive CNS depression. Risk D: Consider therapy modification
Difelikefalin: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis
(doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is not
recommended. Risk C: Monitor therapy
Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of
other CNS agents (eg, opioids, barbiturates) with concomitant use. Risk D: Consider therapy modification
Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. Risk X: Avoid combination
Esketamine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. Risk X: Avoid combination
Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. Management: Reduce the dose of CNS
depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory
depression). Use non-CNS depressant alternatives when available. Risk D: Consider therapy modification
Gabapentin: Cetirizine (Systemic) may enhance the CNS depressant effect of Gabapentin. Cetirizine (Systemic) may decrease the
serum concentration of Gabapentin. Risk C: Monitor therapy
Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents
(Prokinetic). Risk C: Monitor therapy
Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse
effects may be increased. Risk C: Monitor therapy
Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation).
Risk X: Avoid combination
Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination
Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase. Risk C: Monitor therapy
HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS
depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression
in any patient receiving hydroxyzine together with another CNS depressant. Risk D: Consider therapy modification
Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination
Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. Risk C: Monitor therapy
Kava Kava: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Kratom: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination
Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and
of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant
effects. Close monitoring for CNS depressant effects is necessary. Risk D: Consider therapy modification
Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. Risk X: Avoid combination
Lisuride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Lofexidine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may
enhance the CNS depressant effect of CNS Depressants. Management: Reduce the usual dose of CNS depressants by 50% if starting
methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression. Risk D:
Consider therapy modification
Metoclopramide: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. Risk C: Monitor therapy
Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents. Risk C: Monitor therapy
Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. Risk C: Monitor therapy
Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease
the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. Risk C: Monitor therapy
Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination
Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use
of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if
alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy
modification
Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. Risk X: Avoid combination
Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination
Oxomemazine: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination
Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products. Management: Consider
alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants
(including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use Risk D:
OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of
oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative
treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification
Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. Risk X: Avoid combination
Perampanel: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Pilsicainide: May increase the serum concentration of Cetirizine (Systemic). Cetirizine (Systemic) may increase the serum
concentration of Pilsicainide. Risk C: Monitor therapy
Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. Risk C: Monitor therapy
Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant. Risk X: Avoid combination
Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride. Management: Patients on
drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride. Risk X: Avoid
combination
Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. Risk X: Avoid combination
Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. Risk C: Monitor therapy
Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract. Risk X: Avoid
combination
Procarbazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. Risk C: Monitor therapy
Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. Risk X: Avoid combination
Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of
neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS
depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal
ideation, aggression, mania). Risk D: Consider therapy modification
ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. Risk C: Monitor therapy
Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. Risk C: Monitor therapy
Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced. Risk
C: Monitor therapy
Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin. Management: Avoid concomitant use of
anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin. Risk D:
Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant
and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant
with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification
Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. Risk X: Avoid combination
Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like
Diuretics. Risk C: Monitor therapy
Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. Risk X: Avoid combination
Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Risk C: Monitor therapy
Trimeprazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination
Valerian: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand
sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is
recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Risk D: Consider therapy
modification
Food Interactions
Cetirizine's absorption and maximal concentration are reduced when taken with food. Management: May be taken without regard to
meals.
Pregnancy Considerations
Guidelines for the use of antihistamines in the treatment of allergic rhinitis or urticaria in pregnancy are generally the same as in
nonpregnant females. Cetirizine may be used when a second generation antihistamine is needed. The lowest effective dose should be
used (BSACI [Powell 2015]; BSACI [Scadding 2017]; Zuberbier 2018).
Breastfeeding Considerations
Cetirizine is present in breast milk.
Drowsiness and irritability have been reported in breastfed infants exposed to antihistamines (Ito 1993). In general, second generation
antihistamines (eg, cetirizine) are less sedating as compared to their first generation counterparts. If a breastfed infant is exposed to a
second generation antihistamine via breast milk, they should be monitored for irritability, jitteriness, or drowsiness (Butler 2014).
When treatment with an antihistamine is needed in breastfeeding women for the treatment of rhinitis or urticaria, a second generation
antihistamine, such as cetirizine, is preferred. The lowest effective dose should be used (BSACI [Powell 2015]; BSACI [Scadding 2017];
Butler 2014; Zuberbier 2018).
Antihistamines may decrease maternal serum prolactin concentrations when administered prior to the establishment of breastfeeding
(Messinis 1985).
Monitoring Parameters
Relief of symptoms, sedation, mental alertness, and anticholinergic effects.
Mechanism of Action
Competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract
Pharmacokinetics
Onset of action: Suppression of skin wheal and flare: Oral: 20 to 60 minutes.
Duration of action: Suppression of skin wheal and flare: Oral: ≥24 hours.
Absorption: Rapid.
Distribution: Children: 0.7 L/kg; Adults: 0.56 L/kg (Simons 1999).
Protein binding, plasma: Mean: 93%.
Metabolism: Limited hepatic.
Half-life elimination: Children: 6.2 hours; Adults: 8 hours.
Time to peak, serum: Oral: 1 hour; IV: 108 seconds.
Excretion: Urine (70%; 50% as unchanged drug); feces (10%).

Pricing: US
Capsules (ZyrTEC Allergy Oral)
10 mg (per each): $0.57
Chewable (Cetirizine HCl Oral)
5 mg (per each): $2.47 - $5.36
10 mg (per each): $2.47 - $5.36
Chewable (ZyrTEC Childrens Allergy Oral)
2.5 mg (per each): $0.98
10 mg (per each): $0.85
Chewable (ZyrTEC Oral)
10 mg (per each): $0.85
Solution (Quzyttir Intravenous)
10 mg/mL (per mL): $372.00
Solution (ZyrTEC Childrens Allergy Oral)
1 mg/mL (per mL): $0.10
5 mg/5 mL (per mL): $0.10
Tablet, orally-disintegrating (ZyrTEC Allergy Childrens Oral)
10 mg (per each): $1.00
Tablets (Cetirizine HCl Oral)
5 mg (per each): $2.49 - $2.50
10 mg (per each): $0.05 - $2.50
Tablets (ZyrTEC Allergy Oral)
10 mg (per each): $1.04
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided
when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine
the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate
any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.
Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to
accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or
consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Brand Names: International

Aceterin (EE, LV);
Aceto (LT);
Acidrine (CO);
Acitrin (BD);
Acura (SE);
Adezio (SG);
Agelmin (GR, SG);
Alarid (LK);
Alatro (MY);
Alercet (CO, EC,
PE);
Alercina (ES);
Alergine (ID);
Alerid (CZ, EG);
Alerid-10 (ZW);
Alertop (CL, PY);
Allercet (ZW);
Allergy-Care (IL);
Allerkid (PH);
Allersan (BG);
Allertek (UA);
Alyr (LV);
Alzene (AU);
Alzyr (FI);
Alzytec (SG);
Amertil (UA);
Aricetin (KR);
Arix (LK);
Artiz (BH, SA);
Ascet (ET);
Askey (PH);
Askey
DT (PH);
Atopix (AR);
Atrizin (SG);
Bluetec (VN);
Cabal (AR);
Cemediz (VN);
Ceritec (MY, SG);
Cetallerg (CH, LB);
Cetigen (HU);
Cetihexal (BR);
Cetihis (HK, MY, TH);
Cetimax (NO);
Cetimed (LB);
Cetiram (GR);
Cetirax (CO);
CetirHexal (AT);
Cetirin (HK);
Cetiristad (AT, BG);
Cetix (PT);
Cetixin (CZ, DE, SK);
Cetizin (BD);
Cetrak (EG, LB);
Cetrimed (TH);
Cetrine (CN, IE);
Cetrix (LT, LV);
Cetriz (IE);
Cetro (QA, SA);
Cetymin (ID);
Cezera (LT);
Cezin (IN, LK);
Epirizine (EG);
Estin (ID);
Falergi (ID);
Finallerg (BH, JO, KW, LB, SA);
Gencet (AE);
Glotrizine (AE, QA);
Green Nose
(KR);
H-One (PH);
Hismazine (MY);
Histacet (ZW);
Histacetin (UY);
Histazine (IL);
Histec (FI);
Hyperreact (LU);
Lergium (PE);
Letizen (HR, SK);
N-Alergya (IL);
Nohist (SA);
Noler (BD);
Nosemin (KR);
Omcet (AE, BH, JO, KW, QA, SA);
Parlazin (HK, HU);
Prixlae (PH);
Rancet (AU);
Razene
(NZ);
Reactin (BG);
Reactine (BE, DE, MX);
Rigotax (CL);
Rolinoz (UA);
Ronex (LK);
Ryvel (ID);
Ryzen (ID);
Selitex (KR);
Simtec (MY);
Stamidix
(IT);
Sunizine (SG);
Sutac (TH);
Talzic (VE);
Temprazin (PH);
Terizin (PY, SG);
Texzine (PH);
Tirizine (AU);
Triz (TH);
Trizin 5 (PH);
Virlix (ES, FR,
MX, PH);
Xero-Sed (IN);
Zensil (TH);
Zericin (PH);
Zertin (ID);
Zertine (AU, TH);
Zetaler (PE);
Zetalerg (BR);
Zetop (NZ);
Zilarex (AU);
Zinecet
(AU);
Zirec (TR);
Zirizine (AU);
Zirpine (IE, MT);
Zirtec (IT);
Zirtek (GB, IE, UA);
Zirtin (IN);
Zodac (CZ, RU, SK, UA);
Zyllergy (IL);
Zyncet (ZW);
Zyrac (TH);
Zyrak (SY);
Zyrcon (TH);
Zyrfar (CO);
Zyrlex (SE);
Zyrrtec (VN);
Zyrtec (AE, AR, AT, AU, BE, BG, BH, BR, CH, CL, CN, CR, CY, CZ, DE,
DK, DO, EC, EE, EG, ES, FI, FR, GT, HK, HN, HU, IN, JO, KR, KW, LB, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PT, QA, RO, RU,
SA, SI, SK, SV, TH, TR, UY, VE, ZA);
Zyrtec Allergy (BB);
Zyrtec Childrens (BB);
Zyrtec-R (SG)
For country abbreviations used in Lexicomp ( show table)
Use of UpToDate is subject to the Terms of Use.
REFERENCES
1. Adelsberg BR. Sedation and performance issues in the treatment of allergic conditions. Arch Intern Med. 1997;157(5):494-500. [PubMed 9066452]
2. Afonso N, Shetgaonkar P, Dang A, Rataboli PV. Cetirizine-induced anaphylaxis: a rare adverse drug reaction. Br J Clin Pharmacol. 2009;67(5):577-578.
doi:10.1111/j.1365-2125.2009.03394.x [PubMed 19552754]
3. American Academy of Pediatrics (AAP). Cough and cold medicines should not be prescribed, recommended or used for respiratory illnesses in young children.
Updated June 12, 2018. Available at http://www.choosingwisely.org/clinician-lists/american-academy-pediatrics-cough-and-cold-medicines-for-children-under-four/.
4. American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). Pediatrics. 1997;99(2):268-278.
[PubMed 9024461]
5. Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. Philadelphia, PA: American College of
Physicians; 2007, p 97, 169.
6. Asero R. New-onset urticaria. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 19, 2021.
7. Awni WM, Yeh J, Halstenson CE, Opsahl JA, Chung M, Matzke GR. Effect of haemodialysis on the pharmacokinetics of cetirizine. Eur J Clin Pharmacol. 1990;38(1):67-
69. doi:10.1007/BF00314806 [PubMed 1970299]
8. Based on expert opinion.
9. Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. J Am Acad Dermatol. 2014;70(3):417. doi:
10.1016/j.jaad.2013.09.009. [PubMed 24528912]
10. Caffarelli C, Paravati F, El Hachem M, et al. Management of chronic urticaria in children: a clinical guideline. Ital J Pediatr. 2019;45(1):101. doi: 10.1186/s13052-019-
0695-x. [PubMed 31416456]
11. Campbell RL, Kelso JM. Anaphylaxis: emergency treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 25, 2021.
12. Castells MC, Matulonis UA, Horton TM. Infusion reactions to systemic chemotherapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com.
Accessed December 10, 2020.
13. Centers for Disease Control and Prevention (CDC). Infant deaths associated with cough and cold medications--two states, 2005. MMWR Morb Mortal Wkly Rep.
2007;56(1):1-4. [PubMed 17218934]
14. Cetirizine hydrochloride syrup [prescribing information]. Carmel, NY: Silarx Pharmaceuticals; May 2014.
15. Cetirizine tablet [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; February 2012.
16. Cheng A. Emergency treatment of anaphylaxis in infants and children. Paediatr Child Health. 2011;16(1):35-40. [PubMed 22211074]
17. Cicardi M, Aberer W, Banerji A et al; HAWK under the patronage of EAACI (European Academy of Allergy and Clinical Immunology). Classification, diagnosis, and
approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69(5):602-616. doi:
10.1111/all.12380. [PubMed 24673465]
18. Corsico AG, Leonardi S, Licari A, et al. Focus on the cetirizine use in clinical practice: a reappraisal 30 years later. Multidiscip Respir Med. 2019;14:40.
doi:10.1186/s40248-019-0203-6 [PubMed 31827796]
19. Croitoru D, Brooks SG, Piguet V, MacGillivray L. Cetirizine-induced psychosis in a young adult with erythema multiforme. BMJ Case Rep. 2021;14(2):e241393.
doi:10.1136/bcr-2020-241393 [PubMed 33547112]
20. Del Pozzo-Magaña B. Chronic Urticaria in Children: A Review. EMJ Dermatol. 2017;5(1):74-82.
21. deShazo RD, Kemp SF. Pharmacotherapy of allergic rhinitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 10,
2020.
22. Durham CG, Thotakura D, Sager L, Foster J, Herrington JD. Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions
[published online ahead of print November 12, 2018]. J Oncol Pharm Pract. doi: 10.1177/1078155218811505. [PubMed 30419768]
23. Estelle F, Simons R. H1-receptor antagonists: safety issues. Ann Allergy Asthma Immunol. 1999;83(5):481-488. doi:10.1016/s1081-1206(10)62855-4 [PubMed
10582735]
24. Fong DG, Angulo P, Burgart LJ, Lindor KD. Cetirizine-induce cholestasis. J Clin Gastroenterol. 2000;31(3):250-253. doi:10.1097/00004836-200010000-00016 [PubMed
11034010]
25. Food and Drug Administration (FDA). Most young children with a cough or cold don't need medicines. July 18, 2017. Available at
https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm. Last accessed November 2, 2018.
26. Food and Drug Administration (FDA). Use caution when giving cough and cold products to kids. Updated February 8, 2018. Available at
https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm. Last accessed November 2, 2018.
27. Garden BC, Francois D. Cetirizine-associated delusions and depression in an 18-year-old woman. Clin Neuropharmacol. 2013;36(3):96-97.
doi:10.1097/WNF.0b013e318290b9b2 [PubMed 23673913]
28. Horak F, Stübner UP. Comparative tolerability of second generation antihistamines. Drug Saf. 1999;20(5):385-401. doi:10.2165/00002018-199920050-00001 [PubMed
10348091]
29. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J
Obstet Gynecol. 1993;168(5):1393-1399. [PubMed 8498418]
30. James C, Bernstein JA. Current and future therapies for the treatment of histamine-induced angioedema. Expert Opin Pharmacother. 2017;18(3):253-262. doi:
10.1080/14656566.2017.1282461. [PubMed 28081650]
31. Khan DA. Chronic spontaneous urticaria: Standard management and patient education. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc.
http://www.uptodate.com. Accessed November 24, 2021.
32. Kirkham B. Tumor necrosis factor-alpha inhibitors: An overview of adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com.
Accessed November 2, 2021.
33. Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015. Ann Allergy Asthma Immunol. 2015;115(5):341-384. doi:
10.1016/j.anai.2015.07.019. [PubMed 26505932]
34. Mann RD, Pearce GL, Dunn N, Shakir S. Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice. BMJ.
2000;320(7243):1184-1186. doi:10.1136/bmj.320.7243.1184 [PubMed 10784544]
35. Meltzer EO, Weiler JM, Widlitz MD. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for
seasonal allergic rhinitis. J Allergy Clin Immunol. 1996;97(2):617-626. doi:10.1016/s0091-6749(96)70307-x [PubMed 8621847]
36. Messinis IE, Souvatzoglou A, Fais N, Lolis D. Histamine H1 receptor participation in the control of prolactin secretion in postpartum. J Endocrinol Invest.
1985;8(2):143-146. [PubMed 3928731]
37. Ng KH, Chong D, Wong CK, et al. Central nervous system side effects of first- and second-generation antihistamines in school children with perennial allergic rhinitis:
a randomized, double-blind, placebo-controlled comparative study. Pediatrics. 2004;113(2):e116-e121. doi:10.1542/peds.113.2.e116 [PubMed 14754980]
38. Noiri E, Ozawa H, Fujita T, Nakao A. Pharmacokinetics of cetirizine in chronic hemodialysis patients: multiple-dose study. Nephron. 2001;89(1):101-104.
doi:10.1159/000046050 [PubMed 11528239]
39. Pompili M, Basso M, Grieco A, Vecchio FM, Gasbarrini G, Rapaccini GL. Recurrent acute hepatitis associated with use of cetirizine. Ann Pharmacother.
2004;38(11):1844-1847. doi:10.1345/aph.1E162 [PubMed 15383643]
40. Powell RJ, Leech SC, Till S, et al. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015;45(3):547-565. doi:
10.1111/cea.12494. [PubMed 25711134]
41. Quzyttir (cetirizine) [prescribing information]. Deerfield, IL: TerSera Therapeutics LLC; March 2020.
42. Reactine (cetirizine) [product monograph]. Markham, Canada: McNeil Consumer Healthcare; March 2021.
43. Reactine 20 mg Tablet (cetirizine) [product monograph]. Markham, Canada: McNeil Consumer Healthcare; March 2021.
44. Romo CA, Joshi KG, Waters BM. Involuntary movements associated with cetirizine use. Am J Psychiatry. 2011;168(8):855. doi:10.1176/appi.ajp.2011.11040534
[PubMed 21813500]
45. Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (revised edition 2017; first
edition 2007). Clin Exp Allergy. 2017;47(7):856-889. [PubMed 30239057]
46. Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr
Crit Care Med. 2009;10(2):256-259. [PubMed 19188870]
47. Sheikh A, Ten Broek V, Brown SG, Simons FE. H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review. Allergy. 2007;62(8):830-837. doi:
10.1111/j.1398-9995.2007.01435.x. [PubMed 17620060]
48. Simons FE, Ardusso LR, Bilò MB, et al; World Allergy Organization. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol.
2011;127(3):587-593.e1-22. doi: 10.1016/j.jaci.2011.01.038. [PubMed 21377030]
49. Simons FE, Ebisawa M, Sanchez-Borges M, et al. Actualización de 2015 de la base de evidencia: Pautas de anafilaxia de la Organización Mundial de Alergia. Órgano
mundial de alergias J . 2015;8(1):32. doi: 10.1186/s40413-015-0080-1. [PubMed 26525001 ]
50. Simons FE, Simons KJ. Farmacología clínica de los nuevos antagonistas de los receptores H1 de histamina. Clin Pharmacokinet . 1999;36(5):329-352. [PubMed
10384858 ]
51. Zuberbier T, Aberer W, Asero R, et al. La guía EAACI/GA²LEN/EDF/WAO para la definición, clasificación, diagnóstico y manejo de la urticaria. alergia _
2018;73(7):1393-1414. doi: 10.1111/all.13397. [PubMed 29336054 ]
52. Zuraw B. Una descripción general del angioedema: características clínicas, diagnóstico y manejo. Publicar TW, ed. A hoy. Waltham, MA: UpToDate Inc.
http://www.uptodate.com . Consultado el 22 de febrero de 2019.
53. Zyrtec Allergy (cetirizina) [información de prescripción]. Fort Washington, Pensilvania: McNeil Consumer Healthcare; recibido en diciembre de 2021.
54. Zyrtec (clorhidrato de cetirizina) [información de prescripción]. Ciudad de Nueva York, Nueva York: Pfizer Labs; mayo de 2006.
Tema 113446 Versión 421.0

Cetirizine (Systemic) - Drug Information - UpToDate

Cargado por

Información del documento

Título original

Derechos de autor

Formatos disponibles

Compartir este documento

Compartir o incrustar documentos

Opciones para compartir

¿Le pareció útil este documento?

¿Este contenido es inapropiado?

Copyright:

Formatos disponibles

Cetirizine (Systemic) - Drug Information - UpToDate

Cargado por

Copyright:

Formatos disponibles

13/10/22, 18:18 Cetirizine (systemic): Drug information - UpToDate

Reimpresión oficial de UpToDate ®

Cetirizina (sistémica): información sobre medicamentos

Copyright 1978-2022 Lexicomp, Inc. Todos los derechos reservados.

Nombres de marca: EE. UU.

Marcas comerciales: Canadá

Rinitis alérgica o conjuntivitis 

IV, Oral: 10 mg en dosis única ( Ref ).

Angioedema, alérgico agudo o idiopático recurrente 

Infusion reaction, premedication 

Urticaria, new onset and chronic spontaneous 

Urticaria, new onset and chronic spontaneous:

IV: 10 mg once daily as needed.

Dosing: Kidney Impairment: Adult

Altered kidney function:

CrCl >31 mL/minute: No dosage adjustment necessary.

CrCl 11 to ≤31 mL/minute: 5 mg once daily.

Dosing: Hepatic Impairment: Adult

(For additional information see "Cetirizine (systemic): Pediatric drug information")

Allergic symptoms, hay fever 

Allergic symptoms, hay fever:

Children ≥6 years and Adolescents: Oral: 5 to 10 mg once daily.

Anaphylaxis; adjunctive for cutaneous symptoms 

Infants ≥6 months and Children <2 years: Oral: 2.5 mg once.

Children 2 to 5 years: Oral 2.5 to 5 mg once.

Children >5 years and Adolescents: Oral: 5 to 10 mg once.

Rhinitis, allergic (perennial):

Infants 6 to <12 months: Oral: 2.5 mg once daily.

Infants ≥6 months to Children ≤5 years: 2.5 mg every 24 hours.

Children ≥12 years and Adolescents: 10 mg every 24 hours.

Oral: Limited data available (Ref):

Children 2 to 5 years: Oral: 2.5 to 5 mg once daily.

Children >5 years and Adolescents: Oral: 5 to 10 mg once daily.

Urticaria, chronic spontaneous 

Infants 6 to <12 months: Oral: 2.5 mg once daily.

Children 6 to 11 years: Oral: 5 mg once daily or twice daily (Ref).

Children ≥12 years and Adolescents: Oral: 10 mg once daily (Ref).

Dosing: Kidney Impairment: Pediatric

Infants, Children, and Adolescents:

GFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.

GFR 10 to 29 mL/minute/1.73 m2: Decrease dose by 50%.

GFR <10 mL/minute/1.73 m2: Not recommended.

Intermittent hemodialysis or peritoneal dialysis: Decrease dose by 50%.

Dosing: Hepatic Impairment: Pediatric

Dosing: Older Adult

Capsule, Oral, as hydrochloride:

Solution, Intravenous, as hydrochloride [preservative free]:

Quzyttir: 10 mg/mL (1 mL)

Solution, Oral, as hydrochloride:

Generic: 5 mg/5 mL (120 mL, 473 mL, 480 mL)

Tablet, Oral, as hydrochloride:

All Day Allergy: 10 mg [DSC] [contains corn starch]

Allergy (Cetirizine): 10 mg [scored]

Allergy Relief (Cetirizine): 10 mg

Allergy Relief Cetirizine: 5 mg [contains corn starch]

Allergy Relief Cetirizine: 10 mg

Allergy Relief Cetirizine: 10 mg [contains corn starch]

Allergy Relief/Indoor/Outdoor: 10 mg [scored]

Tablet Chewable, Oral:

Tablet Chewable, Oral, as hydrochloride:

ZyrTEC: 10 mg [dye free; contains corn starch]

ZyrTEC Childrens Allergy: 10 mg [dye free; contains corn starch]

Tablet Disintegrating, Oral, as hydrochloride: